About Us

We’re Beta Bionics.

Born out of a real customer need from one of our own. A family learning to manage life, after their infant son developed type 1 diabetes.

To us, it’s personal.

Many on our team live with diabetes or care for people who do. It’s these very real, very personal experiences that have shaped and guided our way from day one.

It’s driven us to want to make a difference. To strive to improve the lives of people living with diabetes and reduce their data and decision-making overload.

At Beta Bionics, we get it. We understand the physical, cognitive, and emotional impacts of diabetes within our community.1 It’s a powerful and inspiring community to be part of.

Knowing from personal experience the many challenges and pressures that people with diabetes cope with motivates our team to not accept the status quo of diabetes management.

We’re not happy that fewer than 1 in 5 people in the U.S. with type 1 diabetes achieve the American Diabetes Association therapy goal.2 That’s not good enough. And we’re on a mission to change that.

Hear our stories.


Ed's Story

Allie's Story

Alli's Story

Brian's Story

Amanda's Story

Jeanne's Story

Stuart's Story

Kate's Story

Veena's Story

The cognitive and emotional burden of type 1 diabetes.

The immense cognitive load and emotional burden of managing type 1 diabetes, coupled with rising health inequality, has created a perfect storm for many.3

80% of people with diabetes live with uncontrolled blood glucose and are at risk from complications.2

Achieving consistent glycemic control in type 1 diabetes is incredibly difficult to achieve. Especially for people with constantly fluctuating blood sugar levels. No wonder 80% are not reaching goal.2

Add in the 42 factors known to affect blood glucose levels such as stress and weather – and you can start to see how big a burden the data and decision-making overload can be.1 When you think of all those varying decisions and ever-changing factors, you can get a sense of what people with diabetes and their caregivers face on a daily basis. It’s a constant battle to try to control the uncontrollable.

Technology for type 1 diabetes has advanced so much recently, but, sadly, the advances seem to only serve the few like those who think like high-tech engineers, or the wealthy or even those who are just plain lucky enough to live in a zip-code with specialist help and advice.

When you see the scale of the problem, it becomes clear what we’re pushing against. And that’s why, for this community, we’re so committed to making change happen.

Sleep, eat, decide, repeat.


Arlene's Story

Xavier's Story

Patty's Story

Our mission and vision.

We’re here to bring innovative type 1 diabetes management solutions to the many, not the few. Bringing better access to better solutions – and a better life for those living with diabetes.

At Beta Bionics, we know instinctively that each person with diabetes has different needs, experiences and resources. The community is not all the same, it’s a group of uniquely different individuals that we’re here to help.

Whatever health inequalities or other challenges you face, we’re committed to bringing forward solutions that enhance your experience in managing diabetes.


Over 12 years of clinical research and 20 pre-pivotal trials

Company founded on October 21, 2015

Locations in California and Massachusetts

B Corp, Public Benefit Corporation

Who we are.

At Beta Bionics, we’re a people-focused company, here to serve the wider diabetes community. As you’d expect, we’ve got incredible technical expertise and skills on our team to enable us to do that.

But just as important, our people are a great bunch of human beings too. All committed and passionate in helping our community live fuller, more enjoyable lives.

References:3. Brown A. 42 Factors That Affect Blood Glucose?! A Surprising Update. [online]. Available from: https://diatribe.org/42factors [Accessed June 2021].2. Foster NC, et al. Diabetes Technol Ther. 2019;21(2):66-72.1. Pallayova M and Taheri S. Diabetes Spectrum. 2014;27(2):143-149.